Table 3.
Group I WetBond | Group II Clinpro | p-value | ||||
---|---|---|---|---|---|---|
N | % | N | % | |||
3 months | Alpha | 35 | 87.50% | 33 | 82.50% | 0.589# |
Bravo | 4 | 10.00% | 4 | 10.00% | ||
Charlie | 1 | 2.50% | 3 | 7.50% | ||
6 months | Alpha | 32 | 80.00% | 30 | 75.00% | 0.820# |
Bravo | 5 | 12.50% | 7 | 17.50% | ||
Charlie | 3 | 7.50% | 3 | 7.50% | ||
9 months | Alpha | 30 | 75.00% | 25 | 62.50% | 0.476# |
Bravo | 7 | 17.50% | 11 | 27.50% | ||
Charlie | 3 | 7.50% | 4 | 10.00% | ||
18 months | Alpha | 16 | 40.00% | 15 | 37.50% | 0.969 |
Bravo | 16 | 40.00% | 17 | 42.50% | ||
Charlie | 8 | 20.00% | 8 | 20.00% | ||
Total | 40 | 100.00% | 40 | 100.00% |
# Denotes statistically not significant using Mann–Whitney U test